医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jain Foundation Clinical Study Exceeds Recruitment Goals

2014年04月03日 AM02:00
このエントリーをはてなブックマークに追加


 

SEATTLE

The Jain Foundation is delighted to announce that 193 patients have been recruited into the Clinical Outcome Study for Dysferlinopathy (COS), exceeding the original goal of 150 patients. Professor Kate Bushby, MD, at Newcastle University and Laura Rufibach, PhD, at the Jain Foundation are co-leading this multi-year study, running in 14 centers worldwide. The study is projected to cost over $3M and is funded entirely by the Jain Foundation.

Dysferlinopathy, also called Limb Girdle Muscular Dystrophy type 2B (LGMD2B) or Miyoshi myopathy, is a rare genetic disease that causes progressive muscle weakness. “Because the normal disease progression has not yet been defined, the main goal of the Clinical Outcome Study is to measure disease progression in patients at all phases of the disease and to identify tests that can be used in clinical trials. This study is a critical step towards developing a therapy for this disease because it will make it possible to test the effectiveness of potential drugs and interventions,” explains Dr. Rufibach.

The recruitment of this large number of people affected by such a rare disease is a real indication of the dedication of the study teams and the enthusiasm of the patients to participate in research,” said Professor Bushby. Dr. Plavi Mittal, President and CEO of the Jain Foundation, confirmed this saying, “Because we are testing as much as possible in this study, we are asking a lot from everyone, especially the patients. I am continually impressed by the commitment of the patients and staff at all of our 14 COS centers.” The study centers are located in the United Kingdom, United States, Japan, Australia, Germany, France, Spain, and Italy. For more information about the study, visit www.jain-foundation.org/dysferlinoutcomestudy.

ABOUT DYSFERLINOPATHY (LGMD2B/MIYOSHI MYOPATHY)

Dysferlinopathy is a rare muscular dystrophy caused by mutations in the dysferlin gene. It has multiple clinical manifestations, the most common of which are Limb Girdle Muscular Dystrophy type 2B and Miyoshi Myopathy. Muscle weakness typically begins in the late teens to early 20s and patients become wheelchair-bound approximately 10 years after the onset of muscle weakness.

ABOUT THE JAIN FOUNDATION

The Jain Foundation (www.jain-foundation.org) is a privately funded not-for-profit corporation based in Seattle. It is focused on finding a therapy for muscular dystrophies caused by dysferlin deficiency (LGMD2B/Miyoshi Myopathy).

ABOUT NEWCASTLE UNIVERSITY

Newcastle University is a public research university located in Newcastle upon Tyne in the United Kingdom. The dysferlin gene was first identified at Newcastle University by Prof Bushby’s team. This 70-person muscle team based in the Institute of Genetic Medicine has a range of ongoing research projects focused on the delineation of the best care and new treatments available for muscular dystrophy and other rare diseases (www.treat-nmd.eu).

CONTACT

Jain Foundation
Elaine Lee, 425-882-1492
Research Program
Officer
admin@jain-foundation.org

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作